Serological features of antibodies to protamine inducing thrombocytopenia and thrombosis

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 2, 2015, Pages 249-255

  Panzer, Simon ^a   Schiferer, Arno ^a   Steinlechner, Barbara ^a   Drouet, Ludovic ^b   Amiral, Jean ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HÔPITAL LARIBOISIÈRE   (France)

^c SYSMEX CORPORATION   (Japan)

Author keywords

protamine sulfate antibodies; serology; thrombocytopenia; thrombosis

Indexed keywords

ARGATROBAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; PADGEM PROTEIN; PROTAMINE; PROTAMINE SULFATE ANTIBODY; PROTEIN ANTIBODY; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; WARFARIN; ANTIBODY;

ADULT; AGED; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL OXYGENATION; FEMALE; GENERAL CONDITION DETERIORATION; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART HEMODYNAMICS; HEART TRANSPLANTATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; INSULIN TREATMENT; ISCHEMIC CARDIOMYOPATHY; LEG THROMBOSIS; LUNG EMBOLISM; MALE; MIDDLE AGED; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; PLATELET AGGREGATION ASSAY; PRIORITY JOURNAL; SEROLOGY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOTAL ARTIFICIAL HEART; VERY ELDERLY; BLOOD; COMPLICATION; DIAGNOSTIC PROCEDURE; IMMUNOLOGY; INTENSIVE CARE UNIT; LEUKOCYTE; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; CLINICAL LABORATORY TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTENSIVE CARE UNITS; LEUKOCYTES; MALE; MIDDLE AGED; PLATELET ACTIVATION; PROTAMINES; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84920869645     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0664     Document Type: Article

References (26)

1. Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, et al. Antibodies to macromolecular platelet factor 4 heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995;73:21-8.
2. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation 2004;110:454-8.
3. Greinacher A. Heparin-induced thrombocytopenia: frequency and pathogenesis. Pathophysiol Haemost Thromb 2006;35:37-45.
4. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-hepa-rin complex as the major antigen. Thromb Haemost 1994;71: 247-51.
5. Poncz M. Mechanistic basis of heparin-induced thrombocytope-nia. Semin Thorac Cardiovasc Surg 2005;17:73-9.
6. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001;113:886-90.
7. Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007;5:1666-73.
8. McFarland J, Lochowicz A, Aster R, Chappell B, Curtis B. Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia. Am J Hematol 2012;87:776-81.
9. Amiral J, Marfaing-Koka A, Wolf M, Alessi MC, Tardy B, Boyer-Neumann C, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associ-ated thrombocytopenia. Blood 1996;88:410-6.
10. Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD. The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol 2000;67:471-8.
11. Amiral J, Peyrafitte M, Vissac A. Association of protamine sulfate antibodies with'Pseudo-HIT' in heparin treated patients. Haemostaseologie 2009;PP4.4-9:A65.
12. Bakchoul T, Zöllner H, Amiral J, Panzer S, Selleng S, Kohlmann T, et al. Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood 2013;121:2821-7.
13. Lee GM, Welsby IJ, Phillips-Bute B, Ortel TL, Arepally GM. High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood 2013;121:2828-35.
14. Pouplard C, Leroux D, Rollin J, Amiral J, May MA, Gruel Y. Incidence of antibodies to protamine sulfate/heparin complexes incardiac surgery patients and impact on platelet activation and clinical outcome. Thromb Haemost 2013;109:1141-7.
15. Kolde HJ, Habrecht U, von Hesberg J, Panzer S, Seidel H, Bakchoul T, et al. Multicentric validation of a rapid assay for heparin-induced thrombocytopenia with different specimen types. Blood Coagul Fibrinolysis 2014;25:6-9.
16. Singla A, Sullivan MJ, Lee G, Bartholomew J, Kapadia S, Aster RH, et al. Protamine-induced immune thrombocytopenia. Transfusion 2013;53:2158-63.
17. Kelton JG, Sheridan D, Brain H, Powers PJ, Turpie AG, Carter CJ. Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 1984;103: 606-12.
18. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombo-cytopenia. Thromb Haemost 1991;66:734-6.
19. Gremmel T, Kopp CW, Seidinger D, Koppensteiner R, Steiner S, Panzer S. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. Eur J Clin Invest 2013;43: 689-97.
20. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-65.
21. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007;35:1165-76.
22. Al-Mondhiry H, Pierce WS, Basarab RM. Protamine-induced throm-bocytopenia and leukopenia. Thromb Haemost 1985;53:60-4.
23. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulatingmonocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin. Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-7.
24. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002-6.
25. Khairy M, Lasne D, Brohard-Bohn B, Aiach M, Rendu F, Bachelot-Loza C. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates; Thromb Haemost 2001;85:1090-6.
26. Cuker A, Cines DB. Protamine-induced thrombocytopenia? Blood 2013;121:2818-9.